Skip to content
Lincoln Pharmaceuticals logo

Lincoln Pharmaceuticals

LINCOLN NSE
₹510.35 +6.00 (+1.19%)
P/E
10.60
View as Markdown
MCP
Close 4 Nov 2026 ₹510.35 −12.75 −2.44% 1Y
Start ₹523.10

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
16.00%
Debt to Equity
0.01
EPS (TTM)
₹48.16
Book Value
₹405.16
Market Cap
—
P/E (TTM)
10.60
P/B
1.26
ROE
12.00%
Dividend Yield
0.36%
EBITDA
₹131 Cr
52W High
₹770.00
52W Low
₹440.00
Day Range
₹498.00 – ₹513.90
Volume
26,006

Peer Comparison

Healthcare › Pharmaceuticals

Lincoln Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Lincoln Pharmaceuticals (this company)
₹510.3510.60₹1,011 Cr1.260.36%12.00%16.00%₹694 Cr₹97 Cr
Median 8 companies₹1,587.7037.20₹1,25,337 Cr4.570.47%16.25%16.90%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 100/100

Category scores

Quality
62
Good
Returns, margins, earnings quality 22% weight
Valuation
87
Strong
Cheap vs sector & own history 24% weight
Growth
36
Poor
Sales & profit trajectory 9% weight
Financial Health
80
Strong
Solvency, leverage, coverage 9% weight
Momentum
18
Poor
Trend strength, vol-adjusted 12% weight
Ownership
34
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

4
  • The company has delivered a poor sales growth of 9.61% over past five years.
  • Company has a low return on equity of 13.6% over last 3 years.
  • Earnings include an other income of Rs.42.4 Cr.
  • Dividend payout has been low at 4.11% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1261
OscillatorsBearish261
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
39.05
Neutral
MACD (12,26,9)
−19.08
Bearish
SMA (50)
576.94
Bearish
SMA (200)
593.57
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+5.31%
5Y+9.62%
3Y+9.58%
1Y+7.70%
TTM+10.00%

Net profit

Net profit growth by window
10Y+13.87%
5Y+7.26%
3Y+6.43%
1Y+7.32%
TTM+11.49%

Operating cash flow

Operating cash flow growth by window
10Y+8.95%
5Y+8.97%
3Y+39.56%
1Y+13.98%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+4.36 pp
5Y−5.91 pp
3Y−3.04 pp
1Y−1.76 pp
TTM−1.78 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹360 Cr
Mar 2018₹361 Cr
Mar 2019₹366 Cr
Mar 2020₹386 Cr
Mar 2021₹424 Cr
Mar 2022₹472 Cr
Mar 2023₹510 Cr
Mar 2024₹581 Cr
Mar 2025₹623 Cr
Mar 2026₹671 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹28.00 Cr
Mar 2018₹35.00 Cr
Mar 2019₹49.00 Cr
Mar 2020₹51.00 Cr
Mar 2021₹62.00 Cr
Mar 2022₹69.00 Cr
Mar 2023₹73.00 Cr
Mar 2024₹93.00 Cr
Mar 2025₹82.00 Cr
Mar 2026₹88.00 Cr

Quarterly Results

₹ Cr
LINCOLN quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
136
156
146
142
147
161
147
168
154
163
166
187
177
191
Expenses
115
125
117
124
125
133
123
141
130
138
143
162
150
168
Operating Profit
21
31
30
18
23
28
24
27
24
25
24
25
27
24
OPM %
15%
20%
20%
13%
15%
18%
16%
16%
15%
16%
14%
13%
15%
12%
Other Income
8
9
11
7
10
10
9
−7
15
7
15
−4
24
10
Interest
0
0
0
0
0
0
1
0
0
0
0
0
0
0
Depreciation
3
3
3
3
3
3
3
3
3
4
4
4
4
4
PBT
25
37
38
22
29
35
29
16
35
29
35
17
48
29
Tax %
25%
25%
26%
16%
20%
24%
28%
29%
22%
31%
18%
30%
24%
30%
Net Profit
19
28
28
19
24
26
21
12
28
20
29
12
36
20
EPS (₹)
9.49
13.8
14
9.29
11.82
13.15
10.37
5.78
13.82
9.98
14.28
5.81
18.09
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
LINCOLN profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
266
400
360
361
366
386
424
472
510
581
623
671
694
Expenses
240
359
313
308
299
321
337
376
421
480
522
573
593
Operating Profit
26
41
47
53
68
66
87
96
90
100
102
98
101
OPM %
10%
10%
13%
15%
18%
17%
21%
20%
18%
17%
16%
15%
15%
Other Income
7
7
2
5
5
11
5
10
22
34
22
33
42
Interest
8
10
7
5
4
2
2
1
2
1
2
1
1
Depreciation
5
5
6
6
7
7
8
8
9
11
13
14
15
PBT
20
33
37
46
62
67
84
96
100
122
109
116
128
Tax %
24%
28%
25%
25%
22%
23%
26%
28%
27%
24%
25%
24%
—
Net Profit
15
24
28
35
49
51
62
69
73
93
82
88
96
EPS (₹)
9.2
14.52
14.06
17.31
24.36
25.72
31.12
34.63
36.4
46.58
41.11
43.88
48.16
Div. Payout %
11%
7%
9%
9%
6%
6%
5%
4%
4%
4%
4%
4%
—

Balance Sheet

₹ Cr
LINCOLN balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
20
20
20
20
20
20
20
20
20
20
Reserves
95
124
172
204
249
293
346
413
482
573
652
738
Borrowings
76
78
64
61
34
5
1
2
2
1
0
4
Other Liabilities
70
56
48
62
63
71
85
99
83
106
125
128
Total Liabilities
258
275
305
347
366
389
452
534
587
700
797
890
Fixed Assets
66
98
103
117
121
123
111
132
151
179
182
191
CWIP
3
3
7
0
2
0
2
16
7
3
4
5
Investments
0
0
10
11
18
34
81
97
91
139
174
209
Other Assets
190
174
186
219
225
232
259
290
339
379
437
486
Total Assets
258
275
305
347
366
389
452
534
587
700
797
890

Cash Flow

₹ Cr
LINCOLN cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
25
45
25
27
53
75
69
76
39
63
93
106
Investing
7
−42
−25
−12
−18
−31
−64
−78
−37
−57
−79
−98
Financing
−32
−3
0
−11
−36
−38
−6
−3
−4
−5
−6
0
Net Cash Flow
−1
0
0
3
−1
7
−1
−4
−2
1
8
8
Free Cash Flow
21
11
7
17
38
68
61
31
26
24
74
82
CFO/OP
109
126
74
68
104
137
102
104
77
89
117
135

Ratios

LINCOLN financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
163
73
92
111
122
96
98
90
98
102
97
88
Inventory Days
44
36
63
86
75
95
86
121
106
101
99
94
Days Payable
92
40
54
82
92
102
105
120
77
95
106
100
Cash Conversion Cycle
116
70
100
115
106
88
78
91
126
108
90
82
Working Capital Days
76
31
69
89
113
126
119
113
121
121
116
126
ROCE %
15%
21%
19%
19%
23%
22%
25%
24%
22%
22%
17%
16%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Lincoln Pharmaceuticals insights

67 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 49.78%
  • Public 36.48%
  • Others 9.17%
  • FIIs 4.55%
  • DIIs 0.02%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Lincoln Pharmaceuticals

What does Lincoln Pharmaceuticals Ltd do?
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products
Where is Lincoln Pharmaceuticals Ltd (LINCOLN) listed?
Lincoln Pharmaceuticals Ltd trades as LINCOLN on the NSE and under code 531633 on the BSE.
Which sector does Lincoln Pharmaceuticals Ltd belong to?
Lincoln Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd trades at a PE ratio of 10.60 as of 4 Nov 2026, on earnings per share of ₹48.16, against a book value of ₹405.16 per share.
What is the 52-week high and low of Lincoln Pharmaceuticals Ltd?
Over the last 52 weeks Lincoln Pharmaceuticals Ltd has traded between ₹440 and ₹770 as of 4 Nov 2026.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd has a dividend yield of 0.36%.
What is the Return on Equity (ROE) of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd reported a return on equity of 12.00%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products

Website lincolnpharma.com
CEO Mr. Mahendrabhai Gulabdas Patel B.A, LLB
Employees 1,853
Listed 21 Oct 2004
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LINCOLN.md for Lincoln Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month